title: Neonatal chlamydial pneumonia induces altered respiratory structure and function lasting into adult life.
abstract: Respiratory dysfunction in adults has been correlated with neonatal Chlamydia trachomatis pneumonia in several studies, but a causal association has not been clearly demonstrated. In this study, we examined radial alveolar counts (RACs) by microscopy, and airway and parenchymal lung function using a small animal ventilator in juvenile (5 weeks age) and adult (8 weeks age) BALB/c mice challenged as neonates with Chlamydia muridarum (C. mur) on day 1 or day 7 after birth, representing saccular (human pre-term neonates) and alveolar (human term neonates) stages of lung development, respectively. Pups challenged with C. mur on either day 1 or 7 after birth demonstrated significantly enhanced airway hyperreactivity and lung compliance, both as juveniles (5 weeks age) and adults (8 weeks age), compared with mock-challenged mice. Moreover, mice challenged neonatally with Chlamydia displayed significantly reduced RACs, suggesting emphysematous changes. Antimicrobial treatment during the neonatal infection induced early bacterial clearance and partially ameliorated the Chlamydia-induced lung dysfunction as adults. These results suggest that neonatal chlamydial pneumonia, especially in pre-term neonates, is a cause of respiratory dysfunction continuing into adulthood, and that antimicrobial administration may be partially effective in preventing the adverse respiratory sequelae in adulthood. The results of our studies also emphasize the importance of prenatal screening and treatment of pregnant women for C. trachomatis in order to prevent the infection of neonates.
authors.affiliation: Department of Biology, South Texas Center for Emerging Infectious Disease, University of Texas at San Antonio, San Antonio, TX 78249, USA.
authors.forename: Madhulika
authors.initials: M
authors.lastname: Jupelli
authors.forename: Ashlesh K
authors.initials: AK
authors.lastname: Murthy
authors.forename: Bharat K R
authors.initials: BK
authors.lastname: Chaganty
authors.forename: M Neal
authors.initials: MN
authors.lastname: Guentzel
authors.forename: Dale M
authors.initials: DM
authors.lastname: Selby
authors.forename: Margarita M
authors.initials: MM
authors.lastname: Vasquez
authors.forename: Shamimunisa B
authors.initials: SB
authors.lastname: Mustafa
authors.forename: Barbara M
authors.initials: BM
authors.lastname: Henson
authors.forename: Steven R
authors.initials: SR
authors.lastname: Seidner
authors.forename: Guangming
authors.initials: G
authors.lastname: Zhong
authors.forename: Bernard P
authors.initials: BP
authors.lastname: Arulanandam
mesh_terms: D000375:Aging; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016535:Bronchial Hyperreactivity / Q000209:etiology; D002690:Chlamydia Infections / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D004334:Drug Administration Schedule; D004917:Erythromycin / Q000008:administration & dosage; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008170:Lung Compliance; D051379:Mice; D008807:Mice, Inbred BALB C; D018410:Pneumonia, Bacterial / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D011650:Pulmonary Alveoli / Q000254:growth & development; D012137:Respiratory System / Q000473:pathology* / Q000503:physiopathology*
chemical_list: D000900:Anti-Bacterial Agents; D004917:Erythromycin